Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says

FDA Commissioner Margaret Hamburg said that working within the current regulatory framework rather than seeking new statutory authority to address the development of drugs and accompanying diagnostic tests would be preferable to address personalized medicine questions at the agency